Imgatuzumab
Monoclonal antibody
- none
- 959963-46-3
- none
- V77J4WJF9Z
- D10439
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody[1] that acts as an immunomodulator.[2][3]
The drug was developed by Genentech/Roche.
References
- ^ Kol A, Terwisscha van Scheltinga A, Pool M, Gerdes C, de Vries E, de Jong S (July 2017). "ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells". Oncotarget. 8 (28): 45432–45446. doi:10.18632/oncotarget.17139. PMC 5542198. PMID 28467975.
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e